<DOC>
	<DOC>NCT01710033</DOC>
	<brief_summary>This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dose level was to be selected for dosing in an expanded cohort in Stage 2.</brief_summary>
	<brief_title>A Study Of CP-690,550 In Stable Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Medically stable kidney transplant patients 6 or more months after transplantation. Subjects must be on mycophenolate mofetil 12 gm daily In Cohort 3 (and 4, if conducted) in Stage 1 and the expanded cohort in Stage 2, subjects must be on a calcineurin inhibitorfree regimen. Any rejection episodes in the preceding 3 months. Treated with Thymoglobulin or OKT3 for acute rejection in the past 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>CP-690,550</keyword>
	<keyword>kidney transplant</keyword>
</DOC>